What Is Metastatic Non-Small Cell Lung Cancer and How Is It Treated?

There’s often a rush of new language. Stage 4. Metastatic disease. Biomarkers. Immunotherapy. It can feel as though everyone is speaking in abbreviations just when you need plain answers.

So let’s start there.

Metastatic non-small cell lung cancer means that a non-small cell lung cancer, usually shortened to NSCLC, has spread from where it started in the lung to another part of the body. It is also called stage 4 lung cancer.

That does not mean there is nothing to be done. Treatment for advanced lung cancer has changed significantly, particularly when we understand the biology of the individual cancer properly.

The important thing is to get the diagnosis, staging and molecular testing right before deciding on the best treatment plan.

What is non-small cell lung cancer?

Non-small cell lung cancer is the most common broad group of lung cancers. It includes several subtypes, including adenocarcinoma, squamous cell carcinoma and large-cell carcinoma.

These subtypes can behave differently and may respond differently to treatment. An oncology specialist will look at the precise subtype, the stage of the cancer and its molecular features before recommending a treatment plan. Adenocarcinoma, for example, is more likely to carry certain molecular changes that can be targeted with specific medicines.

Small cell lung cancer is a separate type of lung cancer. It tends to grow and spread differently, so it is treated differently too.

What does “metastatic” mean?

Cancer begins in one place. In this case, the lung.

Metastatic cancer means that cancer cells have travelled through the bloodstream or lymphatic system and settled elsewhere. These are called metastases, secondary cancers or secondary deposits.

They are still lung cancer cells, even if they are found in another organ.

For example, if non-small cell lung cancer spreads to the bone, it is not bone cancer. It is lung cancer that has spread to the bone. That distinction matters because treatment is chosen according to the original cancer type and its molecular features.

Where can non-small cell lung cancer spread?

Metastatic non-small cell lung cancer can spread to different areas of the body. Common sites include the other lung or the lining around the lung, lymph nodes away from the chest, the bones, the liver, the brain and the adrenal glands, which sit above the kidneys.

Not everybody develops symptoms from secondary cancer. Sometimes it’s found on a scan before it causes a problem.

When symptoms do happen, they depend on where the cancer is.

If cancer has spread to bone

Possible symptoms include persistent or deep aching pain, pain that is worse at night, a fracture after a minor injury, and back pain with leg weakness, numbness or changes in bladder or bowel function.

The last group of symptoms needs urgent assessment, as it can indicate pressure on the spinal cord.

If cancer has spread to the brain

Possible symptoms include new or worsening headaches, changes in balance or coordination, weakness or altered sensation, confusion or changes in memory, seizures, and changes in vision.

These symptoms can have other causes, of course. But they should not be ignored.

If cancer has spread to the liver

Some people have no symptoms initially. Others may notice a reduced appetite, nausea, pain or discomfort in the upper abdomen, abdominal swelling and yellowing of the eyes or skin.

If there is fluid around the lung

Cancer can sometimes cause fluid to collect between the lung and chest wall. This is called a pleural effusion.

It can lead to breathlessness, chest discomfort and a dry cough. The fluid can often be drained to improve symptoms, and there are ways to reduce the likelihood of it returning.

How is metastatic non-small cell lung cancer diagnosed?

A diagnosis usually involves several steps. The aim is not simply to confirm that there is lung cancer. We also need to establish exactly what type it is, how far it has spread and what is driving it biologically.

This can take a little time. I know waiting isn’t easy, but this information can materially change the treatment offered.

Scans

Scans are used to understand the extent of disease and plan treatment. They may include:

• CT scans of the chest and abdomen
• PET-CT scans, which can identify areas of active cancer
• MRI scans, particularly where there is a reason to assess the brain
• Other targeted imaging if symptoms or scan findings suggest it is needed

Biopsy

A biopsy takes a small sample of tissue to confirm the diagnosis.

The sample may come from the lung, a lymph node or another area that looks involved on a scan. Depending on the location, this might be done using a bronchoscopy, an ultrasound-guided procedure or a needle biopsy through the skin.

Blood tests

Blood tests help assess general health and how organs such as the liver and kidneys are functioning. This matters when deciding which treatments are safe and appropriate.

In some cases, a blood sample can also be used to look for tumour DNA. This is sometimes called a liquid biopsy. It can be helpful, particularly if there is not enough tissue from the original biopsy, although it does not always replace tissue testing.

Why molecular testing matters so much

This is one of the most important parts of modern lung cancer treatment.

Non-small cell lung cancer is not one single disease. Two people may have the same stage and subtype, but their cancers may be driven by different molecular changes.

Testing the tumour can identify changes in genes or proteins that affect which treatment is likely to work best. These can include changes involving EGFR, ALK, ROS1, KRAS, BRAF, MET, RET or other pathways.

We also usually assess PD-L1. This is a protein that can help guide decisions about immunotherapy.

The practical point is simple. A molecular result may open the door to a targeted treatment that would not otherwise be considered.

That is why it is worth asking whether comprehensive molecular testing has been performed. Particularly in adenocarcinoma, but not only there.

How is metastatic non-small cell lung cancer treated?

Treatment is individual. There is no useful one-size-fits-all answer.

We look at the exact subtype of non-small cell lung cancer, where the cancer has spread, molecular test results and PD-L1 status.

We also look at previous treatment, if any, lung function and overall fitness, symptoms that need urgent attention and what matters most to the patient.

For most people with metastatic disease, treatment aims to control cancer for as long as possible, reduce symptoms and protect quality of life.

This is not a vague consolation prize. It’s the central work of treatment. And for some people, modern treatments can control the disease for much longer than older survival figures might suggest.

Targeted therapy

Targeted therapies are tablets or other medicines designed to block a specific abnormal signal helping cancer cells grow.

They are used when testing identifies a relevant molecular change.

For example, some patients with particular genetic alterations may be offered a targeted drug as their first treatment rather than chemotherapy. These drugs can be very effective, although cancers can adapt over time, so repeat testing and a change of treatment may be needed later.

Targeted treatment is not suitable for everyone. It depends entirely on the biology of the individual tumour.

Immunotherapy

Immunotherapy helps the immune system recognise and attack cancer cells.

It may be offered on its own, or in combination with chemotherapy. The decision depends partly on PD-L1 results, but also on the pace of the cancer, symptoms, other health conditions and the wider clinical picture.

Immunotherapy has made a real difference for some patients with advanced lung cancer. But it’s not a universal answer. Some cancers respond very well, some do not, and some patients are better served by another approach first.

It can also cause immune-related side effects. These happen when the activated immune system causes inflammation in normal tissues, such as the lungs, bowel, liver, skin or thyroid. They need prompt attention rather than stoicism. No prizes are awarded for quietly feeling dreadful.

Chemotherapy

Chemotherapy remains an important treatment for metastatic non-small cell lung cancer.

It may be used:

• Alongside immunotherapy
• When immunotherapy is not suitable
• When there is no targetable molecular change
• After another treatment has stopped working
• To gain control of cancer that is causing significant symptoms

Chemotherapy affects rapidly dividing cells, which is why side effects can include fatigue, sickness, hair loss, infection risk and changes in sensation in the hands or feet.

The experience varies greatly between people and between drug combinations. Supportive medicines have improved a lot, and side effects should be actively managed rather than simply endured.

Radiotherapy and other local treatments

Drug treatment works throughout the body, but sometimes a local treatment is needed to manage a particular area of cancer or a specific symptom.

Radiotherapy can help relieve pain from bone metastases, treat cancer pressing on important structures, control symptoms caused by a tumour in the chest, or treat brain metastases in selected circumstances. It can also be used very precisely to target a small number of secondary sites. In some people, cancer has spread to only a limited number of areas. This is sometimes called oligometastatic disease.

Where appropriate, focused radiotherapy, surgery or another local treatment may be used alongside drug treatment. It will not be right for everybody, and it needs careful discussion, but stage 4 disease does not automatically mean that local treatment has no role.

Surgery

Surgery is less commonly used as the main treatment when non-small cell lung cancer has spread widely.

However, it may still have a role in selected circumstances. This could include managing a particular complication, obtaining tissue for diagnosis or, occasionally, treating limited areas of disease as part of a wider plan.

Again, the detail matters. The phrase “stage 4” covers a broad range of situations.

Clinical trials

Clinical trials are not just for when standard options have been exhausted.

They can be relevant earlier, especially when there is a particular molecular feature, an unusual pattern of disease or a treatment decision where current evidence is evolving.

Trials may provide access to new targeted drugs, new immunotherapy combinations or different ways of sequencing treatment.

It is reasonable to ask about this from the outset. You do not need to wait until you feel you have run out of options.

Supportive care is part of treatment, not separate from it

There is a slightly unhelpful idea that symptom control is what happens when active treatment ends.

That’s not how good cancer care works.

Supportive and palliative care can run alongside chemotherapy, immunotherapy, targeted therapy or radiotherapy. It focuses on symptoms, wellbeing and practical problems that can make life harder.

This may include help with:

• Breathlessness
• Pain
• Fatigue
• Appetite and weight loss
• Sleep
• Anxiety and low mood
• Mobility and rehabilitation
• Financial, work and family concerns

Managing symptoms well can help people feel better, stay more active and tolerate cancer treatment more effectively.

Is a second opinion worthwhile?

Sometimes, yes. A second opinion is not a criticism of the first team.

Lung cancer treatment has become more detailed and more specialised, and complex decisions often benefit from another experienced view. It can be particularly helpful when molecular testing is incomplete, or results are unclear, when several possible treatment approaches exist, when there is limited metastatic disease and local treatment may be an option, when a rare mutation has been identified, or when you feel the plan has been explained but are not yet confident you understand the reasoning behind it.

The goal is not to create delay for the sake of it. It is to make sure the treatment plan is properly tailored before committing to it.

About Dr James Wilson

Dr James Wilson is a consultant clinical oncologist working in private practice in London, with expertise in lung cancer, advanced radiotherapy, immunotherapy, targeted therapies, and systemic cancer care. His consultations include careful review of medical records, scans, diagnosis, and treatment options, with a written report provided after the appointment. He helps patients understand the options available and make more informed decisions about their care.